• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FTC moves to block Thoratec’s buyout of HeartWare

FTC moves to block Thoratec’s buyout of HeartWare

July 30, 2009 By MassDevice staff

The U.S. Federal Trade Commission plans to file a lawsuit seeking to block the proposed $282 million merger of Thoratec Corp. and HeartWare International Inc.

Saying it believes the merger “would substantially reduce competition in the U.S. market for left ventricular devices,” the commission alleged that Thoratec already enjoys a monopoly on the sale of LVADs in the U.S. and would only increase its hegemony if the merger is consummated.

“Thoratec seeks to maintain its monopoly by acquiring HeartWare, thus eliminating the only significant threat to Thoratec’s continued dominance of the LVAD market,” the commission said, according to a press release.

Pleasanton, Calif.-based Thoratec and Framingham, Mass.-based HeartWare both make small, implantable heart pumps designed to assume the left ventricle’s primary role in pumping blood throughout the body.

Thoratec’s HeartMate line are the only two LVADs approved for sale by the Food & Drug Administration. HeartWare’s HVAD device is undergoing clinical trials and is in line to be the next LVAD approved by the FDA, likely in 2012.

In addition to the lawsuit FTC plans to file in U.S. District Court, an administrative hearing on stopping the deal is set for Dec. 28.

Rick Wise, an analyst at Leerink Swann, wrote in a note to clients that the news represents an opportunity to snap up Thoratec shares at a favorable price.

“[Thoratec] shares have come under pressure recently as investors become increasingly anxious about the likelihood of a successful acquisition, and we suspect some of the news may already be reflected in the stock at current levels,” Wise wrote. “We view any weakness as a buying opportunity for two key reasons: 1) We believe [Thoratec] can maintain its leadership position in LVADs and deliver sustainable double-digit top- and bottom-line growth over the next few years, even without HeartWare; and 2) Acquisition resolution — positive or negative — removes an overhang on [Thoratec] shares.”

Wise predicted that the companies will call off the deal to avoid a costly, lengthy legal battle.

Filed Under: Business/Financial News, Structural Heart Tagged With: HeartWare International Inc.

More recent news

  • Pixee Medical reports first knee arthroplasty cases using its augmented reality nav tech
  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy
  • Elucent Medical wins FDA breakthrough nod for in-body spatial intelligence system
  • EndoQuest Robotics completes first cases in pivotal surgical robot trial
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy